Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Resource Center

News
Underrepresentation in GI Cancer Trials Threatens Real-World Applicability
11/12/2025
Juliet Gallagher
A comprehensive review of US gastrointestinal (GI) cancer randomized clinical trials (RCTs) from 2000 to 2024 reveals persistent demographic inequities in trial participation. The study, published in Journal of Gastrointestinal Oncology,...
A comprehensive review of US gastrointestinal (GI) cancer randomized clinical trials (RCTs) from 2000 to 2024 reveals persistent demographic inequities in trial participation. The study, published in Journal of Gastrointestinal Oncology,...
A comprehensive review of US...
11/12/2025
Journal of Clinical Pathways
News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Optimizing Dosing Strategy Demonstrates Cost-Effectiveness Among Emerging Treatments for Refractory mCRC
05/09/2025
Lisa Kuhns, PhD, MD
In patients with metastatic colorectal cancer (mCRC) who have exhausted frontline therapies, regorafenib dose optimization (ReDO) may be the most cost-effective treatment strategy when compared with TAS-102 plus bevacizumab (TAS-BEV) and...
In patients with metastatic colorectal cancer (mCRC) who have exhausted frontline therapies, regorafenib dose optimization (ReDO) may be the most cost-effective treatment strategy when compared with TAS-102 plus bevacizumab (TAS-BEV) and...
In patients with metastatic...
05/09/2025
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
News
Predicting HER2 Expression in Gastric Cancer With a Deep Learning Model
04/07/2025
Juliet Gallagher
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in...
04/07/2025
Journal of Clinical Pathways
News
Evaluating the Cost Benefits and Clinical Potential of Serum Pepsinogen Screening for Gastric Cancer
03/07/2025
Juliet Gallagher
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in...
03/07/2025
Journal of Clinical Pathways
News
Quality Oncology Practice Initiative Finds Low Rates of Pre-Treatment Staging Imaging Among Patients With Rectal Cancer
05/25/2022
Ellen Kurek
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as...
05/25/2022
Journal of Clinical Pathways

Expert Insights

Insights From ASCO 2021
High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
02/19/2021
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The...
02/19/2021
Journal of Clinical Pathways
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
ENGAGING EXPERTS
High Economic Burden of HCC Treated With Loco-Regional Therapies
01/27/2021
01/27/2021
Journal of Clinical Pathways
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
Joanna M. Rhodes, MD, MSCE
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange
Koulopoulos
Videos
Gigatrends Reshaping Global Health Care: Insights for CPC+CBEx 2025
10/31/2025
Thomas Koulopoulos
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos...
10/31/2025
Journal of Clinical Pathways
Kwon Headshot
Interview
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
10/23/2025
Youngmin Kwon
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin...
10/23/2025
Journal of Clinical Pathways
CONFERENCE COVERAGE
CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles
10/22/2025
Lavi Kwiatkowsky
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi...
10/22/2025
Journal of Clinical Pathways

Newsfeed

News
Underrepresentation in GI Cancer Trials Threatens Real-World Applicability
11/12/2025
Juliet Gallagher
A comprehensive review of US gastrointestinal (GI) cancer randomized clinical trials (RCTs) from 2000 to 2024 reveals persistent demographic inequities in trial participation. The study, published in Journal of Gastrointestinal Oncology,...
A comprehensive review of US gastrointestinal (GI) cancer randomized clinical trials (RCTs) from 2000 to 2024 reveals persistent demographic inequities in trial participation. The study, published in Journal of Gastrointestinal Oncology,...
A comprehensive review of US...
11/12/2025
Journal of Clinical Pathways
News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Optimizing Dosing Strategy Demonstrates Cost-Effectiveness Among Emerging Treatments for Refractory mCRC
05/09/2025
Lisa Kuhns, PhD, MD
In patients with metastatic colorectal cancer (mCRC) who have exhausted frontline therapies, regorafenib dose optimization (ReDO) may be the most cost-effective treatment strategy when compared with TAS-102 plus bevacizumab (TAS-BEV) and...
In patients with metastatic colorectal cancer (mCRC) who have exhausted frontline therapies, regorafenib dose optimization (ReDO) may be the most cost-effective treatment strategy when compared with TAS-102 plus bevacizumab (TAS-BEV) and...
In patients with metastatic...
05/09/2025
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
News
Predicting HER2 Expression in Gastric Cancer With a Deep Learning Model
04/07/2025
Juliet Gallagher
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in...
04/07/2025
Journal of Clinical Pathways
News
Evaluating the Cost Benefits and Clinical Potential of Serum Pepsinogen Screening for Gastric Cancer
03/07/2025
Juliet Gallagher
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in...
03/07/2025
Journal of Clinical Pathways
Clinical Pathways NEXT, Free Webinar, CPC, Oncology Pathways
Press Release
HMP Global Launches Clinical Pathways NEXT to Address Real-Time Oncology Pathway Decision-Making
02/03/2026
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation...
02/03/2026
Journal of Clinical Pathways
News
Adoptive Cell Therapy Advances Target Ovarian Cancer Solid Tumor Barriers
01/23/2026
Hannah Musick
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review...
01/23/2026
Journal of Clinical Pathways
News
Medicare Advantage Reduces Use of High-Cost Cancer Drugs Compared With Traditional Medicare
01/22/2026
Lisa Kuhns, PhD, MD
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA)...
01/22/2026
Journal of Clinical Pathways
News
Medicare Advantage Linked to Lower Access to High-Quality Cancer Surgery in US
01/19/2026
Grace Taylor, MS, MA
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found...
01/19/2026
Journal of Clinical Pathways
News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
News
2025 US Cancer Disparities Report Highlights Education, Rural Gaps
01/12/2026
Hannah Musick
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s...
01/12/2026
Journal of Clinical Pathways
News
Real-World Data Show Similar Outcomes for First-Line uHCC Immunotherapy Regimens
01/08/2026
Grace Taylor, MS, MA
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer...
01/08/2026
Journal of Clinical Pathways
News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Regionalized Gastric Cancer Care
08/27/2021
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization...
08/27/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effective Treatment Strategy for Gastric Cancer
08/05/2021
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative...
08/05/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use